The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
GHRP-6 is the founding member of a class that was discovered in reverse: the synthetic compound came first, the receptor came twelve years later, and the natural hormone that was supposed to do what GHRP-6 was already doing came fifteen years after that.
In the late 1970s, Cyril Y. Bowers at Tulane University was studying enkephalin amides — endogenous opioid peptides. While systematically modifying the chemical structure of met-enkephalin to understand structure-activity relationships, his group observed something unexpected: certain modifications produced significant growth hormone release from pituitary cells in culture. This was not what they were looking for. The met-enkephalin opioid system was not known to stimulate GH in this way. Further modifications refined the compound toward maximum GH stimulation while minimizing opioid activity, eventually producing GHRP-6: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The compound was characterized as a potent GH secretagogue in 1984.
What made GHRP-6 pharmacologically interesting beyond its GH-releasing effect was that it was acting through a receptor that nobody had yet identified. The compound clearly worked through something distinct from the GHRH receptor (it acted additively with GHRH, suggesting independent receptor systems) and distinct from any known opioid receptor. For twelve years, GHRP-6 was studied pharmacologically through an unnamed receptor that could be blocked by specific antagonists and characterized by binding assays — but not identified. In 1996, Howard et al. (Science) cloned the receptor and named it GHS-R (Growth Hormone Secretagogue Receptor). The receptor's natural ligand remained unknown. In 1999, Kojima et al. at Kurume University in Japan isolated ghrelin — the stomach-derived peptide that is the endogenous hormone for the GHS-R, now renamed the ghrelin receptor.
THE CENTRAL TENSION
GHRP-6 is the prototype that all subsequent GHRPs improved upon. GHRP-2 was designed to produce more GH with less cortisol and prolactin. Hexarelin was designed for maximum GH potency. Ipamorelin was designed for clean GH release without any cortisol, prolactin, or ACTH elevation. Every refinement step moved away from GHRP-6's profile. And yet GHRP-6 remains in active community use — not despite its problems, but in some cases because of them. The hunger that arrives 20-30 minutes after a GHRP-6 injection is the strongest appetite stimulus any GHRP produces. For a hardgainer struggling to eat enough during a mass phase, this 'side effect' is the feature. GHRP-6 is the unrefined original that knows its place in the protocol architecture.
Based on Cabrales/Fernandez-Perez 2013 (IV data extrapolated to SubQ community context): biphasic distribution and elimination. Distribution phase: rapid; t½α approximately 7.6 minutes (IV). Elimination phase: t½β approximately 2.5 hours. The short distribution half-life means GHRP-6 delivers a discrete pulse of GH stimulation that peaks rapidly and clears within 2-4 hours. The community convention of dosing 1-3 times daily maintains repeated GH pulses while allowing pituitary receptor recovery between injections. Subcutaneous pharmacokinetics will differ from IV (slower absorption, lower Cmax, extended Tmax) — community SubQ protocols are extrapolations from IV PK data.
The GH response to GHRP-6 follows a dose-response curve with a saturation plateau: beyond approximately 1 mcg/kg (roughly 70-100 mcg for an average adult), additional GHRP-6 does not produce significantly more GH release but does produce proportionally more cortisol and prolactin, and more appetite stimulation. This saturation phenomenon provides the pharmacological rationale for the community standard dose of 100-300 mcg rather than higher doses: doses above the saturation point add adverse effects without proportional GH benefit.
Parameter
Standard Protocol
Notes
Dose
100-300 mcg SubQ per injection
100-150 mcg conservative start; 200-300 mcg most common community dose
Frequency
1-3x daily
Before bed (primary); optionally AM fasted and/or pre-workout
Empty stomach requirement
2+ hours post-meal; 20-30 min before eating after injection
Insulin blunts GH release; same rule as all GH secretagogues
Reconstitution
5 mg vial + 2 mL BAC water = 2.5 mg/mL (2,500 mcg/mL)
300 mcg = 12 units on U-100 syringe; 200 mcg = 8 units
Cycle
8-12 weeks on; 4-8 weeks off
Pituitary receptor recovery during off period; no desensitization data specific to GHRP-6
Stacking
+ CJC-1295 no-DAC (GHRH analog) for synergistic GH pulse
GHRH + GHRP synergy well-established; same principle as GH Stack chapter
Monitoring
IGF-1 at baseline + 6-8 weeks; fasting glucose if extended protocol
Same as all GH secretagogues
GHS-R1a (growth hormone secretagogue receptor type 1a) is a Gq-protein coupled receptor expressed most densely in the anterior pituitary (somatotrophs), hypothalamus (arcuate nucleus, ventromedial nucleus), and throughout the gastrointestinal tract (stomach, intestine). GHRP-6 binds GHS-R1a and triggers Gq-PLC-calcium signaling: phospholipase C activation → IP3 generation → intracellular calcium release → GH exocytosis from pituitary somatotroph granules. The 2021 cryo-electron microscopy structure (Nat Commun; Yang et al.) revealed that GHRP-6 binds GHS-R1a in an 'upside-down' orientation relative to ghrelin — ghrelin inserts its N-terminus deep into the receptor's helix bundle; GHRP-6 inserts its C-terminus instead, with the N-terminus facing the extracellular vestibule. Despite this inverted binding mode, GHRP-6 occupies the same orthosteric binding pocket and produces equivalent receptor activation.
GHS-R1a in the arcuate nucleus of the hypothalamus drives the orexigenic (appetite-stimulating) effect. When GHRP-6 reaches hypothalamic neurons, it activates GHS-R1a on NPY/AgRP neurons — the 'hunger neurons' — producing neuropeptide Y and agouti-related peptide release, which signal food-seeking behavior and increase appetite. Simultaneously, GHS-R1a on POMC neurons inhibits the satiety-signaling anorectic neurons. The net result: GHRP-6 produces the same appetite signal as a stomach full of ghrelin — the 'I need to eat now' signal. This begins within 20-30 minutes post-injection, peaks at 45-60 minutes, and resolves over 1-3 hours. The effect is significantly more pronounced with GHRP-6 than with GHRP-2 or ipamorelin, consistent with GHRP-6's stronger GHS-R1a efficacy in hypothalamic appetite circuits.
GHRP-6 stimulates the hypothalamic-pituitary-adrenal (HPA) axis, increasing CRH release and subsequent ACTH-driven cortisol production. It also directly stimulates pituitary lactotrophs to secrete prolactin. Both effects are GHS-R1a-mediated and are significantly more pronounced with GHRP-6 than with ipamorelin. Ipamorelin's key advantage was demonstrating in Raun et al. 1998 (Eur J Endocrinol) that GH release could be achieved without cortisol or ACTH elevation — establishing that GHRP-6's hormonal footprint was a property of the molecule, not an inherent requirement of GHS-R1a activation in the pituitary. In community context: at 100-200 mcg SubQ once or twice daily, GHRP-6's cortisol elevation is moderate and transient; its practical impact on muscle catabolism or body composition is unlikely to be significant for most users. The concern is greater at higher doses (300+ mcg) run multiple times daily over long cycles.
Beyond the GHS-R1a/GH axis, GHRP-6 has demonstrated cytoprotective effects in multiple animal studies that appear to be mediated through CD36 receptor binding rather than GH elevation. Sosa-Hernandez et al. (2024, Biomedicines) showed GHRP-6 prevented doxorubicin-induced myocardial and extramyocardial damage in rats: attenuating pro-oxidant activity, enhancing antioxidant reserves, protecting mitochondrial ultrastructure, and upregulating anti-apoptotic gene Bcl-2. These effects extended beyond the heart to hepatocytes, renal tubular cells, bronchial epithelia, and intestinal enterocytes. This cytoprotective biology is preclinical (animal models only), but represents a mechanistic dimension of GHRP-6 that distinguishes it from purely GH-centric secretagogues. Whether this CD36 pathway is clinically relevant at community SubQ doses in humans is unknown.
GHRP-6 is best understood in relation to what came after it. Every subsequent GHRP was designed to improve on specific GHRP-6 limitations. Understanding the comparison determines which compound is appropriate for which goal.
Feature
GHRP-6
GHRP-2
Ipamorelin
Hexarelin
Structure
Hexapeptide; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Hexapeptide; D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2
Pentapeptide; Aib-His-D-2-Nal-D-Phe-Lys-NH2
Hexapeptide; His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2
Discovery year
1984 (Bowers)
1992 (Bowers)
1998 (Novo Nordisk/Raun)
~1992-1994
GH release potency
Moderate-strong
Strong (more than GHRP-6)
Moderate
Very strong (most potent GHRP)
Cortisol elevation
Significant at standard doses
Significant (similar to GHRP-6)
Minimal — ipamorelin's key advantage
Significant; hexarelin has additional cardiac receptor effects
Prolactin elevation
Significant
Significant
Minimal
Significant
Appetite stimulation
Very strong — strongest of any GHRP; 20-30 min onset
Moderate
Mild
Moderate
Selectivity
Least selective major GHRP
Intermediate
Most selective GHRP; gold standard for clean profile
Least selective; additional cardiovascular effects
Community use
Bulking (appetite asset); lower cost; historical
Potency-seeking; acceptable cortisol trade-off
Most commonly used GHRP; cutting, body recomp, general use
Less common; high potency but hexarelin-specific cardiac concerns
WADA status
S2 — banned
S2 — banned
S2 — banned
S2 — banned
Cabrales A, Gil J, Fernández E, et al. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European Journal of Pharmaceutical Sciences. 48(1-2):40-46. Design: single IV bolus at 100, 200, and 400 mcg/kg in 9 healthy male volunteers; GHRP-6 quantified by LC-MS with stable isotope internal standard; biphasic pharmacokinetic model. Results: distribution half-life (t½α) = 7.6 ± 1.9 minutes; elimination half-life (t½β) = 2.5 ± 1.1 hours; dose-proportional AUC (linear pharmacokinetics); atypical concentration spikes during elimination phase in 4 of 9 subjects. This is the primary published human pharmacokinetic study for GHRP-6 and establishes the biphasic profile that governs community dosing logic.
Multiple human studies established GHRP-6's GH-releasing effect. The saturation dose concept: approximately 1 mcg/kg IV produces near-maximal GH release in healthy subjects; peak GH concentrations of 15-50 ng/mL (15-50 mcg/L) reported across studies. Leal-Cerro et al. (1998) demonstrated that endogenous hypothalamic GHRH is required for the full GH response to GHRP-6 — GHRP-6 and GHRH act synergistically (consistent with the GH Stack chapter's GHRH+GHRP synergy principle). This established the pharmacological rationale for combining GHRP-6 (or any GHRP) with a GHRH analog.
An evolving body of Cuban research (the Center for Genetic Engineering and Biotechnology, Havana) has investigated GHRP-6 for cytoprotective applications beyond GH stimulation. Most current: Sosa-Hernandez et al. (2024, Biomedicines): doxorubicin-induced cardiotoxicity in rats; GHRP-6 prevented myocardial damage through CD36 receptor binding, antioxidant upregulation, and Bcl-2 anti-apoptotic gene expression. Earlier Cuban studies: GHRP-6 in liver fibrosis, ischemia-reperfusion injury, gastric ulcer, and wound healing animal models. These findings are Grade C (animal) and are specific to a Cuban research group with institutional interests in GHRP-6 pharmaceutical development. The cytoprotective data is scientifically interesting; its translation to community SubQ dosing for these endpoints is unestablished.
Evidence
Grade
Key Finding
Cabrales/Fernandez-Perez 2013 (Eur J Pharm Sci; n=9; IV)
B
Biphasic PK: t½α 7.6 min, t½β 2.5h; dose-proportional; first validated human PK data for GHRP-6
Multiple GH stimulation human studies (1984-2000s)
B
Saturation dose ~1 mcg/kg IV; peak GH 15-50 ng/mL; synergy with GHRH established
Leal-Cerro 1998
B
GHRH required for full GH response to GHRP-6; additive mechanism confirmed in humans
Raun et al. 1998 (Eur J Endocrinol; ipamorelin comparison)
B
Ipamorelin achieves GH release without cortisol/ACTH; established GHRP-6's cortisol elevation as molecule-specific, not class-inherent
Sosa-Hernandez 2024 (Biomedicines; rat cardiotoxicity)
C
CD36-mediated cardioprotection independent of GH; antioxidant and anti-apoptotic effects
Cuban cytoprotective series (liver, ischemia, wound, gastric)
C
Multiple animal models; protective effects; single institutional provenance; not independently replicated
Cryo-EM structure Yang et al. 2021 (Nat Commun)
D
GHRP-6 binds GHS-R1a in upside-down orientation vs ghrelin; same orthosteric pocket; receptor activation mechanism confirmed structurally
The hunger is not a side effect. It is a direct pharmacological action at GHS-R1a hypothalamic appetite circuits. Understanding it prevents surprises and allows protocol design that uses it appropriately.
Twenty to thirty minutes after a GHRP-6 injection, a distinct and intense hunger arrives. Community descriptions are consistent across thousands of reports: 'like waking up after not eating for 24 hours'; 'I could eat anything in the kitchen'; 'it hits suddenly, like a switch.' This is NPY/AgRP neuron activation in the arcuate nucleus — the molecular definition of the hunger state. The effect typically peaks at 45-90 minutes and resolves over 1-3 hours. It is significantly more intense than the mild appetite increase occasionally reported with ipamorelin.
For a user in a caloric surplus trying to gain mass, this hunger window is an asset: it is a pharmacologically induced appetite that makes eating large quantities of food easier and more comfortable. For a user in a caloric deficit trying to lose body fat, it is a serious liability: the hunger created by GHRP-6 will make dietary adherence significantly harder and may fully negate any GH-mediated fat loss benefit. This is the central practical reason the community has largely shifted to ipamorelin for cutting and recomposition protocols while retaining GHRP-6 specifically for bulking or in populations where appetite stimulation is therapeutic (illness recovery, chemotherapy patients, wasting conditions).
GHRP-6 FOR APPETITE STIMULATION — THE LEGITIMATE THERAPEUTIC CASE
Beyond athletic and body composition use, GHRP-6's hunger stimulation has a legitimate clinical rationale: in catabolic illness, chemotherapy-induced anorexia, and muscle wasting conditions, the ability to pharmacologically drive appetite and food intake is therapeutically valuable. The ghrelin system is the body's endogenous appetite drive signal, and GHRP-6 is one of the most potent pharmacological activators of that system. This is an area where GHRP-6's 'problem' (powerful hunger drive) becomes a clinical feature rather than a liability.
ACTIVE MALIGNANCY — CAUTION (GH/IGF-1 ELEVATION)
GH and IGF-1 have mitogenic activity. Elevated IGF-1 is associated in epidemiological studies with increased cancer risk for certain tumor types. Active malignancy is a caution for all GH secretagogues including GHRP-6. Physician consultation mandatory for any cancer history before using any GH secretagogue.
GHRP-6 produces moderate, transient cortisol elevation at standard community doses. The cortisol peaks within 30-60 minutes and returns to baseline within 2-4 hours. For most healthy adults at 100-300 mcg per injection, the magnitude of cortisol elevation is unlikely to produce measurable catabolic consequences in the context of appropriate training and recovery. The concern increases with: higher doses (300+ mcg multiple times daily); high baseline stress and cortisol; existing adrenal conditions; or extended cycles without rest periods. Individuals particularly sensitive to cortisol or concerned about the catabolic implications should use ipamorelin instead.
Prolactin elevation from GHRP-6 is real and community-documented. Prolactin promotes breast tissue development and can contribute to gynecomastia, particularly in men with other pro-estrogenic influences (concurrent TRT, aromatizable anabolics, pre-existing gyno sensitivity). The prolactin elevation from GHRP-6 at standard doses is generally transient and moderate; clinical gynecomastia from GHRP-6 alone at community doses is not commonly reported but the mechanism of concern is valid. Monitoring serum prolactin in individuals with gynecomastia history or concurrent androgenic/estrogenic protocols is appropriate.
GH elevation from GHRP-6 produces the same downstream effects as any GH secretagogue: sodium and water retention (mild edema, particularly in hands and feet during loading phase); transient insulin resistance (elevated fasting glucose possible, particularly at higher doses or in pre-diabetic individuals). These effects are common to the class and are not GHRP-6-specific.
Ipamorelin produces a cleaner hormonal profile — GH without cortisol or prolactin. For cutting, body recomposition, and users sensitive to cortisol or prolactin effects, ipamorelin is superior. But GHRP-6's strong appetite stimulation makes it specifically useful when caloric intake is the limiting factor in a mass phase. It is not obsolete; it occupies a different protocol niche. The 'cleanest' compound is not always the right compound for every goal.
Above the saturation dose (~100 mcg, or approximately 1 mcg/kg), additional GHRP-6 does not produce significantly more GH release but does produce proportionally more cortisol, prolactin, and appetite stimulation. Community doses above 300 mcg per injection are entering territory where adverse effects scale faster than GH benefit. The dose-response curve plateaus for GH before it plateaus for cortisol.
Incorrect. GHRP-6 (GHS-R1a) and CJC-1295 no-DAC or sermorelin (GHRH receptor) activate entirely different receptor systems. Their combination produces a synergistic GH pulse that is 3-5x larger than either alone — this is the same GHRH+GHRP synergy documented by Bowers et al. 1991 that underpins the GH Stack chapter. Different receptors, additive-to-synergistic combined effect.
The cytoprotective data (liver fibrosis, cardiac protection, gastric ulcer, wound healing) comes from animal models generated by a single institutional group with commercial interests in GHRP-6 pharmaceutical development. It is preclinical. The CD36-mediated cytoprotective mechanism is scientifically interesting but has not been validated in human controlled trials. Community use of GHRP-6 for organ protection is a Grade C (animal) extrapolation, not a clinically established application.
GHRP-6 is most commonly used in the community in two specific situations: (1) bulking protocols where appetite stimulation is a feature — hardgainers, underweight individuals, and mass-phase athletes who benefit from the pharmacologically driven hunger window for caloric surplus maintenance; (2) historical use by experienced community members who began using GHRP-6 before ipamorelin was widely available and continue with it based on established personal protocol. Among newer community members, ipamorelin has become the default GHRP for most applications, with GHRP-6 specifically chosen when its appetite effect is the goal.
GHRP-6 is widely available from research peptide vendors as lyophilized powder in 5 mg vials. It is generally less expensive per mg than ipamorelin. Quality variables apply: HPLC purity ≥98%; mass spec identity verification (MW 872 Da); endotoxin testing for injectable grade. The common 5 mg vial reconstituted with 2 mL BAC water produces 2.5 mg/mL (2,500 mcg/mL); a 200 mcg dose = 8 units on a U-100 syringe.
Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 54(12):1316-29. [Bowers's own review of GHRP class history and mechanism; the primary author documenting the discovery of GHRP-6 and the class.]
Cabrales A, Gil J, Fernández E, et al. (2013). Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 48(1-2):40-46. [Only published human PK study; IV bolus; t½a 7.6 min, t½b 2.5h; dose-proportional; essential reference.]
Howard AD, Feighner SD, Cully DF, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273(5277):974-7. [GHS-R cloning; the receptor GHRP-6 had been activating for 12 years; foundational molecular pharmacology paper.]
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402(6762):656-60. [Ghrelin discovery; endogenous ligand for GHS-R identified 15 years after GHRP-6; the reverse pharmacology origin story.]
Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 139(5):552-61. [Ipamorelin human pharmacology; established that GH release without cortisol/ACTH is achievable; implicitly demonstrated GHRP-6's cortisol elevation is not inherent to GHS-R1a agonism.]
Sosa-Hernández E, et al. (2024). GHRP-6 prevents doxorubicin-induced myocardial and extramyocardial damage in rats. Biomedicines. [Most current cytoprotective GHRP-6 data; CD36-mediated mechanism; cardiac and multi-organ protection independent of GH; preclinical.]
Yang HY, et al. (2021). Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor. Nat Commun. 12:5064. [Cryo-EM structure of GHS-R1a bound to ghrelin and GHRP-6; upside-down binding mode of GHRP-6; same orthosteric pocket; structural pharmacology of GHS-R1a activation.]
Bowers CY, Sartor AO, Reynolds GA, Badger TM. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 128(4):2027-35. [Foundational GHRH+GHRP synergy paper; GHRH + GHRP-6 produces 2-3x GH pulse vs either alone; basis for all GHRP + GHRH combination protocols.]
GHRP-6 is the founding GHRP — the unrefined prototype that preceded its own receptor's discovery and its natural ligand's identification. It remains in active use not because it's the best GHRP, but because its primary limitation is also, in the right protocol context, its most useful feature.
The compound's story resolves clearly: Cyril Bowers discovered a GH-releasing peptide that activated an unknown receptor for twelve years, and that receptor turned out to be the ghrelin system — one of the most fundamental appetite and energy homeostasis circuits in mammalian biology. Every improvement attempt (GHRP-2, ipamorelin, hexarelin) moved away from GHRP-6's strong appetite drive and cortisol elevation. And yet GHRP-6 survives in the community because the hunger is real, intense, and pharmacologically predictable — exactly what a hardgainer in a mass phase needs. The cytoprotective CD36 biology adds an unexpected dimension that the community has largely not explored. The WADA S2 status is a career-ending concern for competitive athletes. And the empty stomach rule, like all GH secretagogues, is not optional.
— End of GHRP-6 —
THE PEPTIDE BIBLE | GHRP-6 | For Research & Educational Purposes Only
GHRP-6 (Growth Hormone Releasing Peptide-6): synthetic hexapeptide; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; MW 872 Da. Discovered by Cyril Y. Bowers 1984 as met-enkephalin analog modification. REVERSE PHARMACOLOGY: GHRP-6 (1984) → GHS-R cloned (1996, Howard, Science) → ghrelin discovered (1999, Kojima, Nature). WADA S2. NOT FDA-approved. MECHANISM: GHS-R1a agonist (Gq-PLC-Ca2+ pathway); cryo-EM structure (Yang 2021, Nat Commun): upside-down binding orientation vs ghrelin; same orthosteric pocket. PITUITARY: GH exocytosis from somatotrophs. HYPOTHALAMUS (arcuate): NPY/AgRP neuron activation → hunger. HPA axis: CRH → ACTH → cortisol ↑. LACTOTROPHS: prolactin ↑. CD36 receptor: cytoprotective effects independent of GH (Sosa-Hernandez 2024; animal; cardioprotective, hepatoprotective). GHRP CLASS: GH potency = Hexarelin > GHRP-2 > GHRP-6 > Ipamorelin; Cortisol/prolactin = GHRP-2 ≈ GHRP-6 > Ipamorelin; Appetite = GHRP-6 >> GHRP-2 > Ipamorelin. Ipamorelin (Raun 1998): GH without cortisol/ACTH — established GHRP-6's cortisol as molecule-specific, not class-inherent. PHARMACOKINETICS: Cabrales/Fernandez-Perez 2013 (n=9; IV); t½a 7.6 ± 1.9 min; t½b 2.5 ± 1.1h; biphasic; dose-proportional AUC; only published human PK data. SATURATION DOSE: ~1 mcg/kg IV (≈70-100 mcg); above this, cortisol/prolactin scale without proportional GH gain. GH PEAKS: 15-50 ng/mL at saturation dose. SYNERGY WITH GHRH: Bowers 1991; GHRH + GHRP-6 = 2-3x GH vs either alone; different receptors (GHRHR + GHS-R1a). HUNGER: onset 20-30 min post-injection; peaks 45-90 min; resolves 1-3h; strongest of any GHRP; arcuate NPY/AgRP. COMMUNITY PROTOCOL: 100-300 mcg SubQ; 1-3x daily; empty stomach mandatory (insulin blunts GH); bedtime primary injection; reconstitute 5mg/2mL BAC (2,500 mcg/mL); 200 mcg = 8 units U-100. CYCLE: 8-12 weeks; 4-8 weeks off. SAFETY: cortisol (moderate, transient, returns to baseline 2-4h); prolactin (transient; gynecomastia concern with concurrent estrogenic exposure); water retention; insulin resistance (class effect). ACTIVE MALIGNANCY: caution (GH/IGF-1 mitogenic). IGF-1 MONITORING: baseline + 6-8 weeks; target upper half age-appropriate range. CHOOSE GHRP-6 WHEN: bulking; appetite stimulation desired; cost efficiency. CHOOSE IPAMORELIN WHEN: cutting; cortisol/prolactin sensitivity; cleanest profile needed.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.